News

[Hørsholm, January 17th, 2024] – Contera Pharma A/S, a biotech company developing innovative therapies to treat neurological disorders, announce enrolment of the last patient in its Phase 2b clinical trial ASTORIA. The trial aims to evaluate the efficacy of JM-010, a novel therapeutic solution designed to specifically address the pathophysiology underlying Parkinson’s disease dyskinesia. This […]

Contera Pharma, a biotech company developing innovative therapies to treat neurological disorders, and BDD Pharma, a drug delivery company specializing in modified and controlled release oral formulations, announce dosing of first subject in a Phase 1 pharmacoscintigraphic study in healthy volunteers. The study will evaluate a novel delayed-release, dual pulse levodopa / carbidopa tablet (CP-012), […]

Abzu® and Contera Pharma expand their strategic partnership to add drug-target identification to their seminal RNA- and siRNAs therapeutic design platform. Contera Pharma is a Danish biotech company -developing innovative small-molecule and RNA-based therapeutics to address neurological disorders. Their unique R&D model integrates their team of experienced neuroscience drug hunters with cutting-edge technology, like Abzu’s […]

Cambridge UK, and Copenhagen, Denmark, 27 September 2022 – Vernalis Research (“Vernalis”), a fully owned subsidiary of HitGen Inc., and Contera Pharma A/S (“Contera”) are pleased to announce a strategic drug discovery collaboration on an undisclosed target. Under the terms of the agreement, Vernalis and Contera will use their respective expertise in fragment and structure-based drug design […]

Contera Pharma, a biotech company developing innovative therapies to treat neurological disorders, has entered into collaboration with BDD Pharma, a drug delivery company specializing in modified and controlled release oral formulations, to begin the development of a novel formulation of levodopa / carbidopa (CP-012) to specifically treat Parkinson´s disease (PD) patients suffering from nocturnal or […]

Abzu, an applied research startup who has developed a pioneering explainable artificial intelligence (xAI), and Contera Pharma, a biotech company developing innovative therapies to treat neurological disorders, are partnering to design nucleic acid-based medicines. Abzu will collaborate exclusively with Contera Pharma on two undisclosed targets within rare neurological diseases. According to recent research in European […]